

Index

A

Acute respiratory distress syndrome (ARDS), 282
Adenosine triphosphates (ATPs), 185
Adhesion molecules, 132, 135–136
Adipose tissue (AT), 302
AEC1. *See* Alveolar Type I Epithelial Cells (AEC1)
AECII. *See* Alveolar Type II epithelial cells (AECII)
Aerobic metabolism, 185
Aerobic respiration, 183
Airflow obstruction, 285, 288
Airway and vascular remodeling, 168
Airway obstruction, 168
Alveolar type I epithelial cells (AEC1), 5, 28
Alveolar type II epithelial cells (AECII), 28
Alveolarization, 95, 96
Alveolocapillary gas exchange, 188
American Thoracic Society (ATS) guidelines, 285
Angiotensin-2, 142
Anti-infective agents, 87–88
Antioxidant (AO)
 capacity, cell resulting, 6
 defense systems, 186, 187
 endogenous enzymes, 6
 low-molecular weight, 7
 mechanisms, 7
Antioxidant enzymes (AOEs), 327
Apoptosis, 188
Arterial oxygen saturation, 176, 178
Arterial partial pressure of O₂ (p_aO₂), 189
ATP-binding cassette, 118
Attention deficit hyperactivity disorder (ADHD), 285
Azithromycin, 87, 88, 330

B

Baboons, 5
BALF. *See* Bronchoalveolar lavage fluid (BALF)
Barotrauma, 59, 60
Bayley III scales, 193
Bi-level CPAP, 210
Biomarkers
 adhesion molecules, 135, 136
 anti-inflammatory cytokines, 140
 CC10, 140, 141
 chemokines, 133
 enzymes, 139
 fetal lung development, 141
 inflammation, 129
 inflammatory process, 130
 limitations, 143
 NAC, 140
 oxidative stress, 139
 preterm infants, 130
 VEGF, 141
Bombesin-like peptide (BLP), 14
Bone marrow (BM), 302
BOOST II trial, 194
Brain oxygenation, 191
Bronchial hyperresponsiveness, 282, 284–288
Bronchoalveolar lavage fluid (BALF), 8, 60, 130
Bronchopulmonary dysplasia (BPD), 3, 79,
 167, 223, 259, 281
 acinar development, 156
 adult lungs, 157
 airflow limitations, 282
 airway growth, 160
 alveolar and microvascular remodeling, 149
 alveolar growth abnormalities, 160

- Bronchopulmonary dysplasia (BPD) (*cont.*)
- alveolar pathology, 157
 - alveolar simplification and dysmorphic microvasculature, 157
 - alveolarization and pulmonary vascular development, 56
 - alveolarization and vascular development, 69
 - autopsy findings, 156
 - bronchial hyperresponsiveness, 282
 - bronchial lesions or alveolar septal fibrosis, 161
 - cellularity and fibrosis, 156
 - characterized, 169
 - chronic fibroproliferative stage, 154
 - chronic lung disease, preterm infants, 149, 150
 - chronic respiratory disease, 281
 - clinical presentation, 109
 - CNVs, 111
 - definition, 283
 - degree of prematurity, 169, 177
 - description, 243–247
 - diagnostic definition, 167, 169–170
 - elastic fiber architecture, 154
 - epidemiology of, 168–169
 - exogenous surfactant, 156
 - exogenous surfactant and antenatal steroid administration, 149
 - fetal inflammatory response syndrome, 58–59
 - fibroproliferative lung injury, 160
 - fibroproliferative response, 156
 - genetic association, 112
 - genetic variants, 111, 113
 - haplotype, 116
 - HapMap project, 112
 - human genome, 111
 - hyperexpansion and atelectasis, 154
 - in vitro and in vivo data, 55
 - incidence of, 176
 - infection/sepsis, 328
 - inflammation-induced influx, 326
 - intra-amniotic infection and inflammation, 55
 - long-term damage, 154
 - lung function studies, 159, 160
 - lung morphogenesis, 149
 - lung pathology, 55
 - mechanical ventilation, 149
 - miRNA, 117
 - morphometric and biochemical techniques, 157
 - mycoplasma (*see Mycoplasma*)
 - neutrophils and macrophages, 68
 - newborn animal models, 4–5
 - and nitrogen-free radicals, 188
 - nutrition (*see Nutrition*)
 - obstructive bronchiolar lesions, 154
 - old BPD vs. new BPD, 282
 - and O₂ therapy, 185
 - oxidative stress, 115
 - oxidative stress antioxidants, 327
 - oxygen requirement at postnatal ages, 172–175
 - oxygen supplementation, 170–172
 - pathogenesis (*see Hyperoxia*)
 - pathophysiology, 109
 - pediatric scientific community, 281
 - perinatal and neonatal conditions, 161
 - pharmacological interventions, 56
 - population at risk, 177–178
 - postcanalicular lung remodeling, 157
 - postcanalicular lungs, 161
 - postnatal factors, 55
 - pre and postnatal pro-inflammatory conditions, 58, 68
 - precapillary arteriovenous anastomoses, 157
 - premature infants, 299
 - prematurity, 281
 - prematurity-associated lung injury, 56
 - prematurity-associated lung pathology, 150
 - preterm infants, 156, 160
 - pulmonary arteries and intra-acinar arterioles, 156
 - pulmonary function in survivors (*see Preterm birth*)
 - pulmonary hypertension (*see Pulmonary hypertension (PH)*)
 - pulmonary interstitial emphysema, 154
 - pulmonary microvasculature, 157
 - RDS, 55, 169, 281
 - respiratory distress syndrome (RDS), 154
 - septal interstitium, 154
 - severe forms of, 168, 169
 - severity, 288–292
 - severity classification, 175–176
 - SPOCK2 gene, 114
 - surfactant, 149, 327–328
 - susceptibility, 110
 - treatment, 336
 - vascular and airway smooth muscle cell development, 55
 - vascular hypothesis, 157
 - Vitamin D, 115
 - wide spectrum, 150
- Brown's meta-analysis, 192

C

- Calcium (Ca), 232
 - Caspases, 10
 - Cell death
 - caspases and components, 10
 - and hyperoxia-induced lung cell injury, 9–10
 - Cell transplantation, 299
 - mesenchymal stem cells (MSCs)
 - (*see* MSCs transplantation)
 - stem (*see* Stem cell transplantation)
 - Cerebral palsy, 177
 - Chemokines, 133–135
 - Chest radiographs
 - bubbly lung, 245
 - degree of hyperexpansion, 247
 - development of BPD, 247
 - differential diagnosis, 249
 - digital, 247
 - features, 247
 - granular pattern, lung parenchyma, 244
 - honeycomb or spongelike appearance, 245
 - immature lung, 247
 - infancy to adulthood, 248–249
 - leaky lung syndrome (LLS), 244, 248
 - peri- and neonatal care, 247
 - premature infants, 248
 - scoring of chest CT scan, 250
 - scoring systems, 247
 - structural changes, lungs, 247
 - type 1 and type 2 diseases, 247
 - Children's Interstitial Lung Disease (ChILD)
 - Research Network, 157
 - Chorioamnionitis (CA), 79, 85, 86
 - adverse pro-inflammatory conditions, 57
 - animal experiments, 57
 - chronic inflammatory process, 57
 - definition, 56
 - gestation-independent effect, 57
 - lipopolysaccharide (LPS), 57
 - maturational effect, 57
 - microbial colonization, 57
 - microbial invasion/pathological processes, 56
 - microorganisms, 56
 - pro-inflammatory cytokines, 56
 - Ureaplasma* spp., 56
 - utero infection, 56
 - Chronic lung disease (CLD), 156, 157, 169, 193
 - anti-inflammatory mediators, 326
 - infancy, 325
 - inflammation-specific cells, 326
 - mouse models, 328
 - pulmonary infections, 325
 - Chronic obstructive pulmonary disease
 - in adult life, 94
 - airway obstruction, 96
 - asthma and wheezing, 95
 - C/EBPs, 98
 - environmental exposures, 100
 - lung function, 95
 - parental smoking, 100
 - pathology, 93
 - prevalence, 93
 - Clara Cell 10 Protein (CC10), 335, 337
 - Clara cell secretory protein 10 (CC10), 140
 - Closed-loop FiO₂ control system (CLiO), 194
 - Continuous positive airway pressure (CPAP), 60, 200
 - BPD/death rates, 316
 - Bubble, 200
 - INSURE technique, 206–207, 316
 - intubation group, 315
 - modern interfaces, 201
 - neonatal ventilators, 200
 - observational studies, 203–204
 - physiological effects, 200
 - post-extubation period, 201
 - pressure generation and delivery, 200–201
 - pressure-generating devices, 200
 - vs. supplemental oxygen, 201–202
 - weaning preterm infants, 207
 - Copy-number variations (CNVs), 111
 - Cord clamping, 190
 - CPAP. *See* Continuous positive airway pressure (CPAP)
 - Curcumin, 334
 - Cytokine-induced neutrophil chemoattractant-1 (CINC-1), 11
 - Cytokines, 10, 11, 130
- D**
- Dioxygen, 185
 - Docosahexaenoic acid (DHA), 332–333
 - fetal lung growth, 231
 - levels, time of birth, 232
 - parenteral lipid administration, 232
 - source, 232
- E**
- Early-onset sepsis (EOS), 59
 - EGFR. *See* Epidermal growth factor receptor (EGFR)
 - ELBW. *See* Extremely low-birth weight (ELBW)

- Endotracheal ventilation, 200, 201, 203
 EOS. *See* Early-onset sepsis (EOS)
 Epidermal growth factor receptor (EGFR), 35
 Erythropoietin (EPO), 188
 Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), 169
 Extracellular SOD (ecSOD), 7
 Extremely low-birth weight (ELBW), 39, 60, 183
 Extremely preterm infants, 223
 nutritional support (*see* Nutritional support of extremely preterm infant)
 potential effects of undernutrition, 224
- F**
 FEV₁/forced vital capacity (FVC) ratio, 285, 290, 291
 FRC. *See* Functional residual capacity (FRC)
 Free radicals, 185
 Functional residual capacity (FRC), 33, 200
- G**
 Gene expression, 116
 Genetic pathway analyses, 116–117
 Genetic susceptibility, 69
 Glutathione (GSH), 187
- H**
 Hedgehog interacting protein (HHIP), 98
 Hepatocyte growth factor (HGF), 14, 301, 302
 Heterodimeric transcription factor, 188
 High-flow nasal cannulae (HFNC), 211
 vs. nasal CPAP, 211–214
 vs. NIPPV, 212–213
 for weaning from CPAP, 214–215
 High-resolution computed tomography (HRCT)
 adulthood, 254
 BPD patients, 250
 early teenage to adolescence, 246, 253
 evaluation, 249
 infancy and early childhood, 251–253
 lung abnormalities, 249
 multifocal areas, 249
 pulmonary parenchyma, 249
 respiratory dysfunction, 249
 scoring, 252
 scoring systems, 250, 251
 severity of BPD, 249
- HIPERSPACE trial, 213
 Host immune response, 81–82
 Hyaline membrane disease, 153, 154
 Hyperoxia, 5–8, 188, 194
 BLP, 14
 CINC-1, 11
 genetic and environmental factors, 3
 HGF, 14
 IFN γ , 12
 IL-1, 10
 IL-10, 11
 IL-6, 10–11
 IL-8, 11
 KGF, 11
 lung injury, mechanism (*see* Lung injury)
 MCP-1, 11
 MIF, 13
 MMP9, 12
 MT, 15
 newborn animal models, 4–5
 pathology of new BPD, 4
 SIP, 15
 SOD, 15–16
 STOP-ROP trial, 3
 TGF β , 12–13
 TNF α , 13
 VEGF, 13–14
- Hypertension, 259
 pulmonary (*see* Pulmonary hypertension (PH))
 Hypoxemia, 194
 Hypoxia response elements (HREs), 188
 Hypoxia-inducible factor 1 α (HIF-1 α), 6, 184, 189
- I**
 ICAMs. *See* Intercellular adhesion molecules (ICAMs)
 IGF. *See* Insulin growth factor (IGF)
 Infants, 259, 299, 300, 303–307
 Inflammatory cells, 138
 Inhaled nitric oxide (iNO), 269, 329
 Insulin growth factor (IGF), 41
 INSURE technique, 203, 206–207
 Intercellular adhesion molecule-1 (ICAM-1), 136
 Intercellular adhesion molecules (ICAMs), 62
 Interferon gamma (IFN γ), 12
 Interleukin-1 (IL-1), 10
 Interleukin-10 (IL-10), 11
 Interleukin-18 receptor 1 (IL18R1), 114
 Interleukin-6 (IL-6), 10–11
 Interleukin-6 (IL-6) concentration, 326
 Interleukin-8 (IL-8), 11

- Intrauterine infection models, 85–87
 detection, 88
 and lung injury, 81
- Intraventricular hemorrhage (IVH), 320
- Intubation
 BPD, 315
 CPAP, 315
 and mechanical ventilation, 318
- Invasive mechanical ventilation
 AEC1, 28
 AECII, 28
 alveolar development and disruption, 27
 alveolar septation, 39–41
 alveolar–capillary permeability, 29–31
 animal models, 42–43
 cell proliferation, differentiation and apoptosis, 41–42
 chronic lung disease, 27
 EGFR, 41
 ELBW, 39
 endothelial cells, 29
 fibroblasts, 29
 lung development, 39
 lung inflammation and injury, 27
 macrophages, 29
 mechanical injury, 28
 neutrophils and macrophages, 31–32
 saccules, 39
 VEGF, 42
 VILL, 27
- K**
- Keratinocyte growth factor (KGF), 11
- Krebs von den Lungen-6 (KL-6), 142
- L**
- Late-onset sepsis (LOS), 59
- Less invasive surfactant administration (LISA)
 and BPD, 318–321
 death rates, 319
 endotracheal tube, 317
 Magill forceps, 316
 and mechanical ventilation, 317–318
 safety, 321
 sedation/premedication, 316
 VLBW infants, 322
- Long-chain polyunsaturated fatty acids
 (n-3 LCPUFAs), 231, 236
- Long-term consequences of preterm birth
 ADHD, 292
 adulthood, 284
 categories of disease severity, 289
 clinical characteristics of BPD, 289, 290
 dysynaptic/unequal lung growth, 291
 early childhood, 283
 lung function measurements of BPD
 subjects, 290, 291
 mechanical ventilation and oxygen therapy, 292
 mild disease, 289
 neonatal respiratory illness, 291
 NICHD review, 292
 NIH consensus, 289
 oxygen dependency, 288
 oxygen therapy, 290
 pathogenesis, 288
 postnatal risk factors, 288
 retrospective cohort, 290
 retrospective study, 289
 supplemental oxygen, 289
- LOS. *See* Late-onset sepsis (LOS)
- Lung development
 alveolar stage, 153
 canalicular stage, 151
 embryonic stage, 150
 fetal, 150, 151
 organogenesis, 150
 pseudoglandular reflects, 151
 pseudoglandular stage, 151
 saccular (terminal sac) stage, 152, 153
- Lung function, 100
- Lung injury, 5–10, 168, 170, 180
 hyperoxia
 airway epithelial layer thickness and airway smooth muscle area, 8
 airway epithelium serves, 8
 alveolar type II epithelial cells, 7
 cell injury and cell death, 9–10
 childhood wheezing disorders, 8
 HIF-1 α , 6
 human neonates, 7
 macrophage and PMN infiltration, 8
 MnSOD/ecSOD, 7
 Nox, 6
 Nrf2, 7
 O₂, 5
 oxidative stress, 6
 oxygen-induced injury, 6
 P53, 7
 pulmonary microvascular endothelial cells, 5
 RNS, 5–7
 ROS, 5–7
 tracheal aspirates and bronchoalveolar lavage (BAL) fluid, 8
 VEGF, 6

M

- Macrophage migration inhibiting factor (MIF), 13
- Macrophages, 134
- Magnetic resonance imaging (MRI)
 early changes, emphysema, 255
 lack of radiation exposure, 254
 low-density cyst-like focal abnormalities, 255
 preterm infants, 255
 severe BPD, 256
 T1-weighted and proton density-weighted images, 255
- MAPK. *See* Mitogen-activated protein kinase (MAPK)
- Matrix metalloproteinase 9 (MMP9), 12
- Mechanotransduction
 EGFR, 35
 gene expression, 39
 growth factor receptors, 38
 inflammatory response, 35
 integrins–focal adhesions–cytoskeleton, 37–38
 intracellular signaling pathways, 38
 ion channels, 36, 37
 mechanical deformation, 35
 transcription factors, 38, 39
- Medical Research Council (MRC) dyspnea score, 285
- Melatonin (MT), 15
- Mesenchymal stem cells (MSCs), 305, 333
 adult tissues, 302
 AT, 303
 BM, 302, 303
 characteristics, 302
 donor age, 303
 gestational tissues, 303
 transplantation (*see* MSC transplantation)
 umbilical cord and placental tissue, 303
- Migration inhibitory factor (MIF), 137
- Mitochondrial manganese SOD (MnSOD), 7
- Mitogen-activated protein kinase (MAPK)
 signaling, 328
- Mitogen-activated protein kinases (MAPK), 12, 37
- Molecular mechanisms
 alveolar capillary permeability, 65–66
 alveolarization and angiogenesis, 66–67
 cellular and endothelial interaction, 62
 cellular and humoral mediators, 61
 chemotactic and chemokinetic factors, 62
 inflammation, 68
 oxygen radicals and proteolytic mediators, 65
 pro- and anti-inflammatory cytokines, 62–63
 PRRs, 64–65
 repair mechanisms and growth factors, 67
 stem cell therapy, 68
- Monocyte chemoattractant protein-1 (MCP-1), 11
- MSC transplantation
 long-term safety and outcomes, 306
 optimal dose, 305
 optimal timing, 305–306
 phase I clinical trial, 307
- Multiple-banded antigen (MBA)
 size variants, 85
 ureaplasma cell surface MBA protein, 81
 virulence factors, 80
- Mycoplasma, 79, 82–87
 animal models
 human BPD, 82
 intrauterine infection models, 85–87
 mycoplasma infections, 82–84
 pneumonia models, 82–84
Ureaplasma infection, 82, 85
 anti-infective agents, 87–88
 host immune response, 81–82
 microbiology, 80
Mycoplasma hominis (*see* *Mycoplasma hominis*)
Ureaplasma parvum (*see* *Ureaplasma parvum*)
Ureaplasma urealyticum (*see* *Ureaplasma urealyticum*)
 virulence factors, 80–81
- Mycoplasma hominis*
 amniotic fluid isolates, 81
 genitourinary tract commensals, 79
 hydrolyzes arginine, 80
 respiratory samples, 79
- Myelin basic protein (MBP), 306
- N**
- NAD phosphate (NADP), 185
- NADPH oxidase (Nox), 6
- Nasal cannula (NC) flow, 178
- Nasal continuous positive airway pressure (nCPAP), 195
- Nasal intermittent positive pressure ventilation (NIPPV), 204, 329
 history, 208
 in post-extubation period, 209
 physiological effects, 208, 209
 studies, 209–210
- National Centre for Biotechnology Information (NCBI), 111
- National Institute of Child Health and Human Development (NIHCD), 283

- National Institutes of Health (NIH), 170, 175, 289
- Necrotizing enterocolitis (NEC), 187, 331
- Neonatal European Study of Inhaled Steroids (NEUROSIS), 332
- Neonatal intensive care unit (NICU), 183
- Neonatal Oxygenation Prospective Meta-analysis Collaboration study (NeOProm), 193
- Neonatal ventilators, 200
- Neonatal-Onset Respiratory Disease, 117–119
 - ABCA3* gene, 118
 - SFTPB gene, 118
 - SFTPC gene, 119
 - TTF1, 119
- Neurally adjusted ventilatory assist (NAVA) mode, 209
- Newborn animal models
 - hyperoxia, 4, 5
- Newborns
 - lung disease, 13
 - mice, 7
 - Nrf2*^{-/-} mice, 7
 - SOD, 16
 - with RDS, 15
 - treatment, 12
- NICHD Neonatal Research Network, 169, 176, 178, 179
- Nicotinamide adenine dinucleotide (NAD), 185
- Nicotinamide adenine dinucleotide phosphate (NADPH), 328
- Nitrogen-free radicals, 188
- Nuclear factor kappa B (NF-κB), 187, 327
- Nuclear factor-erythroid 2-related factor 2 (*Nrf2*), 7
- Nutrition, 225–228, 235–236
 - calcium (Ca), 232–233
 - carbohydrates, 230
 - degree of critical illness in AGA infants
 - energy and fluid intake, 226
 - outcome variables, 227
 - development of BPD, 224, 225
 - extremely preterm infant (*see* Nutritional support of extremely preterm infant)
 - fluids usage, 229–230
 - guidelines (*see* Standardized feeding guidelines)
 - inositol, 230
 - magnesium (Mg), 233
 - NICU, 223
 - phosphorus (P), 233
 - post-discharge (*see* Post-discharge nutrition)
 - protein, 231
 - selenium (Se), 235
 - triglycerides and fatty acids, 231–232
 - Vitamin A, 233–234
 - Vitamin E, 234, 235
- Nutritional support of extremely preterm infant
 - analysis, 225
 - daily energy and fluid intakes, first 3 weeks, 225
 - mediation framework, 226
 - severity of critical illness for AGA infants, 225
 - SGA infants, 226
- O**
- O₂ load, 191
- Oxidative phosphorylation, 185
- Oxidative stress, 187
- Oxidative stress biomarkers, 192
- Oxidized glutathione (GSSG), 191
- Oxygen
 - and mechanical ventilation, 14
 - oxygen-induced injury, 6
 - ROS, 5
 - saturation, 3
 - STOP-ROP trial, 3
- Oxygen requirement
 - at 36 weeks postmenstrual age, 173–175
 - at day 28, 172–173
 - during first 4 weeks, 170–171
 - for more than 28 days, 172
- Oxygen Supplementation. *See* Supplemental oxygen
- P**
- Paracrine effects, 301
- Paracrine mediators, 301, 302
- Patent ductus arteriosus (PDA), 169
- Pattern recognition receptors (PRRs), 64, 81
- PCNA. *See* Proliferating cell nuclear antigen (PCNA)
- Pediatric Academic Societies (PAS) annual meeting, 192
- Pentoxifylline, 330–331
- Perinatal care, 183
- Periventricular leukomalacia (PVL), 187
- Peroxisome Proliferator-Activated Receptor gamma Agonists (PPARγ), 334
- Phosphodiesterase inhibitors, 335
- Phosphorus (P), 233
- Pneumonia models, 82–84
- Polyunsaturated fatty acids (PUFA), 187
- Positive end expiratory pressure (PEEP), 208

- Post-discharge nutrition
 anthropometric, 235
 BPD, 236
 management, very low birth weight infants, 235
 NICU, 235
 planning, 235
 preterm infants, 235
 primary care pediatrician, 235
- Postnatal risk factors
 hyperoxia and hypoxia, 60–61
 infection, 59
 mechanical ventilation, 59–60
- Preductal pulse oximetry (SpO₂), 189
- Premature, 299, 300, 303, 305, 306
- Premature infants, 167, 169, 173, 180
 oxygen dependency, 172
 with respiratory failure, 168
 respiratory control function, 178
 supplemental oxygen, 170
- Prematurity, 150, 157, 160
 consequences, 183
 lung development, 183
- Prenatal steroid therapy, 168
- Prenatal steroids, 4
- Preterm, 95, 99
- Preterm birth, 283–284
 BPD (*see* Bronchopulmonary dysplasia (BPD))
 bronchial hyperresponsiveness, 285–288
 bronchodilator response, 286
 demographic and clinical information, 285, 286
 FEV₁/FVC ratio, 285
 hospital discharge diagnosis, 284, 285
 long-term respiratory outcomes (*see* Long-term consequences of preterm birth)
 methacholine challenge, 287
 MRC dyspnea score, 285
 pulmonary function test, 285
 pulmonary lung function, 285, 287
 SF-36v2, 285
 SGRQ, 285
- Preterm infants, 315, 316, 319, 321
 chorioamnionitis, 62
 lung pathology, 55
 oxygen saturation, 60
 TNF- α positive macrophages, 63
- Proinflammatory cytokines, 136–138
- Proliferating cell nuclear antigen (PCNA), 42
- Prolyl-hydroxylase enzymes (PHD1–3), 188
- Prostacyclin derivatives, 271
- PRRs. *See* Pattern recognition receptors (PRRs)
- Pulmonary, 259
 hypertension (*see* Pulmonary hypertension (PH))
 Pulmonary hypertension (PH), 261–264, 269–271
 artery pressure measurement, 260
 biomarkers, 268
 cardiac catheterization, 266, 267
 chronic respiratory diseases, childhood, 259
 clinical features, 265
 development, 262
 echocardiographic diagnosis, 266
 echocardiography, 265, 266
 ELBW infants, 260
 heterogeneity and variability, 273
 intra- or extra-cardiac shunts, 261
 LVDD, infants, 265
 management, 271–273
 mimic, 265
 prevalence, 260
 PVD (*see* Pulmonary vascular disease (PVD))
 risk, anesthesia, 267
 risk, growth-restricted infants, 261
 tracheobronchomalacia, 267
 treatments, infants and children, 268
 vasoconstriction, 268
 vasodilators (*see* Pulmonary vasodilators)
 vasorelaxation, 269
 vein stenosis, 265
 VLBW infants, 259
- Pulmonary hypertension in infants, 168
- Pulmonary vascular disease (PVD), 259
 alveolarization, 261
 alveologenesis and gas exchange, 264
 angiotensin (ANG)/Tie-2 ligand/receptor system, 263
 damage and thickening of pulmonary circulation, 262
 endothelial monocyte-activating polypeptide II (EMAP II), 262
 endothelial nitric oxide synthase (eNOS), 264
 hypoxia-inducible factor-1 α (HIF-1 α), 263
 low-density lipoprotein receptor-related protein 5 (LRP5), 264
 noxious stimuli, 261
 nuclear factor kappa B, 263
 pathogenesis, 261
 Tie2 signaling, 264
 vascular endothelial growth factor (VEGF), 262
 vasodilation and vasoconstriction, 261

- Pulmonary vascularization bed, 184
- Pulmonary vasodilators
- endothelin 1 (ET-1), 270
 - iNO, 269
 - oxygen therapy, 269
 - prostacyclin (PGI₂), 271
 - sildenafil, 270
- Pulse oximeter, 194
- R**
- Radiology of BPD, 247, 249, 254
- acute respiratory distress, 243
 - adolescence/adulthood, 256
 - chest (*see* Chest radiographs)
 - chronic disease, 245
 - HRCT technique (*see* High-resolution computed tomography (HRCT))
 - MRI (*see* Magnetic resonance imaging (MRI))
 - period of regeneration, 244
 - syndrome, 243
 - transition to chronic disease, 244
- Randomized controlled trials (RCTs), 207, 329
- RDS. *See* Respiratory distress syndrome (RDS)
- Reactive nitrogen species (RNS), 186
- Reactive oxygen species (ROS), 139–140, 185, 186
- receptor for advanced glycation end products (RAGE), 98
- Receptor tyrosine kinase (RTK) receptors, 13
- regulated on activation, normal T cell expressed and secreted (RANTES), 135
- Respiratory distress syndrome (RDS), 55, 168, 200
- Respiratory failure in infants, 167–169
- Respiratory health, 285, 287, 288, 292
- Respiratory Health Survey, 284
- Resuscitation, 189, 190
- Retinopathy of prematurity (ROP), 187
- S**
- Saint George's Respiratory (SGRQ) questionnaires, 285
- Saugstad's meta-analysis, 193
- Secretory leukocyte protease inhibitors (SLPIs), 139
- Selenium (Se), 235
- SF-36v2, 285
- Sildenafil, 270
- Single nucleotide polymorphisms (SNPs), 81, 111
- Smoking, 93, 100
- Solithromycin, 87
- Sphingosine kinase 1 (SphK-1), 15
- Sphingosine-1-phosphate (S1P), 15
- Standardized feeding guidelines
- caloric requirements, 229
 - clinical evaluation, 229
 - colostrum/donor milk, 228
 - development, 228
 - enteral nutrition, 229
 - evidence-based strategy, 228
 - exceptions and non-exceptions, 228
 - extremely preterm infants, 228
 - implementation, 229
 - measurements, growth, 229
 - nutritional practices, 228
 - parenteral fluid support, 228
 - reduction, growth failure, 229
 - total parenteral nutrition (TPN), 228
 - TPN, 228
- StarSync[®] module, 208
- Stem cell therapy, 299
- exogenous administration, 299
 - MSCs (*see* Mesenchymal stem cells (MSCs))
 - transplantation (*see* Stem cell transplantation)
- Stem cell transplantation, 302
- engraftment and differentiation, 300–301
 - EPCs, ECFCs, 304
 - ESCs, 304
 - MSCs (*see* Mesenchymal stem cells (MSCs))
 - paracrine effects, 301
 - paracrine mediators, 301, 302
 - therapeutic potential, 300
 - UCB MNCs, 303, 304
- Steroids
- hydrocortisone, 332
 - inflammation, 331
 - intestinal perforation, 331
 - neurodevelopmental side effects, 332
 - short-term side effects, 331
 - treatment, 331
- Stretch stress
- animal studies, 328
 - hyperoxia, 328
 - noninvasive ventilation approach, 328
- Superoxide dismutase (SOD), 15–16, 327
- Supplemental oxygen, 170, 171, 180
- and premature infants, 170
 - cumulative duration, 172
 - indicator of lung disease, 176
 - need for, 176
- Supplemental Therapeutic Oxygen for Prethreshold Retinopathy of Prematurity (STOP-ROP) trial, 3

- Surfactant, 202
- Surfactant protein-A (SP-A)-deficient mice, 84
- surfactant proteins, 118
- Synchronized NIPPV (SNIPPV), 208
- vs. NCPAP, 208
- pressure generation and delivery, 208–209
- T**
- The Cochrane Review, 331
- Thyroid transcription factor-1 (TTF1), 119
- Tissue inhibitor of metalloproteases (TIMPs), 138
- TLRs. *See* Toll-like receptors (TLRs)
- Toll-like receptors (TLRs), 64
- host immune response, 81
- Tracheobronchomalacia, 272
- Transforming growth factor (TGF), 141
- Transforming growth factor beta (TGF β), 12–13
- Transient receptor potential vanilloids (TRPV), 37
- TRPV. *See* Transient receptor potential vanilloids (TRPV)
- Tumor necrosis factor alpha (TNF α), 13, 187
- U**
- UCB MNCs, 303, 304
- Ureaplasma parvum*
- anti-infective agents, 87–88
- genitourinary tract commensals, 79
- intrauterine infection models, 85–87
- pneumonia models, 82–84
- serovar, 80
- wild-type mice, 84
- Ureaplasma urealyticum*
- anti-infective agents, 87–88
- genitourinary tract commensals, 79
- intrauterine infection models, 85–87
- pneumonia models, 82–84
- serovars, 80
- V**
- Vascular cell adhesion molecules (VCAMs), 62
- Vascular endothelial growth factor (VEGF), 13–14, 42, 137, 184, 189, 301, 302
- lung injury, 6
- VCAMs. *See* Vascular cell adhesion molecules (VCAMs)
- VEGF. *See* Vascular endothelial growth factor (VEGF)
- Venous cord blood, 191
- Ventilator-induced lung injury (VILI), 27
- air–liquid interfaces, 33
- alveolar epithelial barrier function, 34
- alveolar epithelial plasma membrane stress failure, 34
- atelectrauma, 33
- biotrauma, 33
- calcium, 34
- deformation-induced remodeling, 33
- endothelial and epithelial barriers, 35
- epithelial and endothelial cells, 33
- factors, 33
- FRC, 33
- heterogeneity, 33
- lung volumes, 33
- lysosomes, 34
- mechanical strain, 32
- plasma membrane, 34
- preterm lambs, 33
- shear stress, 32
- surfactant-deficient lung, 33
- vesicular lipid trafficking*, 34
- volutrauma, 33
- Very low birth weight (VLBW), 192, 282, 284, 288, 289, 325
- VILI. *See* Ventilator-induced lung injury (VILI)
- Virulence factors
- ammonia, 80
- MBA, 80
- PAMP, 80
- U. parvum* serovar 3 clinical strain SV3F4 genome, 80
- Ureaplasma* spp., 81
- ureaplasma, 80
- Vitamin A
- administration, 234
- and iNO, 234
- benefits, 234
- deficiency, preterm infants, 233
- prevention, 234
- risk of BPD, 234
- storage and preparation, 234
- supplementation, ELBW infants, 233
- Vitamin D (VD), 115, 333
- Vitamin E, 234
- W**
- Weaning preterm infants, 207
- Wilson–Mikity syndrome, 153
- Window of vulnerability, 58, 69